Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.99 HKD | -2.51% | -6.17% | +4.64% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.64% | 636M | |
+33.07% | 698B | |
+26.51% | 568B | |
-4.33% | 358B | |
+19.17% | 328B | |
+3.97% | 283B | |
+16.42% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+7.62% | 165B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- UBS Adjusts Ocumension Therapeutics’ Price Target to HK$15.90 From HK$23.20, Keeps at Buy